Open label extension study of oral triple kinase inhibitor in IPF pts. BIPI 1199.33
Trial ID or NCT#
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToRosemary Vojnik
Go Back To The Trial